Investigator Sponsored Studies

Investigator Sponsored Studies (ISS)

Click Here to Apply

Alkermes seeks to support investigator research designed and conducted by independent physicians and scientists. Alkermes has supported more than 40 clinical trials since the beginning of the ISS program in 2008. Alkermes can provide VIVITROL®, ARISTADA® and/or placebo to the ISS programs it supports. In addition, there may be limited financial support available. In general, the research we support is based in the U.S. with experienced researchers who have an established history of successfully receiving independent funding.

Areas of Interest

Substance Use Disorders

  • Improving treatment initiation and adherence
  • Long-term treatment outcomes
  • Implementing MAT into healthcare systems
  • Cognitive effects of OUD and MAT
  • Special Populations:
    • Adolescents/young adults
    • Pregnant women
    • OUD and co-occurring substance use disorders


  • Integration of Long-Acting Injectables (LAIs) into psychosocial strategies
  • Patient/Family or Clinician engagement strategies in LAI use
  • Demonstration of LAI benefits in special populations
  • Criminal justice
  • Schizophrenia with substance use disorder
  • ARISTADA use in early stages of illness
  • Patients transitioning across treatment services

ISS applications are reviewed by a cross functional team of medical and scientific staff to consider patient safety, operational feasibility, scientific merit, and alignment with Alkermes research goals and needs. Applications can be submitted in one of two ways:

  • A pre-protocol submission where your application will serve as your proposal, but you have not developed a protocol yet; or
  • A protocol submission where your protocol is already developed and ready for review. To complete an application, please login here.

Please be aware that Alkermes cannot guarantee support for ISS program applications and all decisions regarding such support will be made at Alkermes’ sole discretion. ISS submissions are accepted on a rolling submission basis.